Home | Publications | Therapeutic place holder
place holder place holder

Therapeutic

Enzyme Inhibitors with Broad Therapeutic Applications


Publication Date   June 2006
Publisher   Business Communications Company
Product Type   Report
Pages   165
ISBN Number   not applicable
Product Code   BCC037
Ask a question about this product?

Price £2,410.00

approximately: $4,503 | €3,057

Summary


The aim of this report is to provide a range of information-from detailed market analyses through industry trends-to quantify and qualify the market for therapeutic enzyme inhibitors with large markets and/or broad therapeutic applications.

This report offers a broad detailed overview of enzyme inhibitors currently on the market and those in late-stage clinical trials. The information and analysis presented in this report are important assets in decision-making for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking and deal creation, and to consultants to the pharmaceutical and biotechnology industry. The study provides a comprehensive analysis of the current markets for enzyme inhibiting drugs and, in particular, the market potential of promising drugs and technologies under development.

Scope Of Study

This report contains:

  • The major current and emerging therapeutic markets for enzyme inhibitors used in human therapeutics,
  • A discussion of the biochemistry for enzyme inhibitors and classes of enzyme inhibiting products with broad current or potential therapeutic applications or large markets,
  • A synopsis of more than 100 enzyme inhibitors, including those currently marketed and those in Phase II or later development,
  • An overview of the leading indications for available and emerging enzyme inhibitors. These include selected indications for asthma and chronic obstructive pulmonary disease (COPD), cardiovascular diseases, erectile dysfunction, gastrointestinal disorders, hepatitis B virus infection, hepatitis C virus infection, herpesvirus infections, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and rheumatoid arthritis and related inflammatory diseases,
  • Forecasts for the global market, through 2011,
  • Company Profiles emphasizing companies that lead the pharmaceutical and biotechnology industry in the research and development of enzyme-inhibiting drugs.

Report Highlights

  • During the forecast period, enzyme-inhibiting drugs are projected to be introduced for new indications including asthma and chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, hepatitis C and intermittent claudication.
  • Recent withdrawals of products in the COX-2 inhibitor class along with recent and future introductions of novel products in other classes will rearrange the market share of categories in the enzyme inhibitor sector. Overall, the market for products included in this report is expected to show an average annual growth rate (AAGR) of approximately 6.7% from 2005 to 2011, increasing from $29.2 billion to $43.1 billion.
  • Of all the inhibitor categories, COX-2 and PDE4 will see increases in revenue share for the period 2005 to 2011. Cox-2 inhibitors' share will grow from 12.7% to 18.9%, while PDE4 inhibitors will increase from zero in 2005 to 3.6% in 2011.

Content


  • Introduction
    • Objectives And Goals Of The Study
    • Contributions Of The Study And For Whom
    • Scope And Format
    • Methodology
    • Information Sources
    • About The Author
    • Related BCC Work Credentials Including Work Done By Other Authors
    • BCC Online Services
    • Disclaimer
  • Executive Summary
    • Summary Table: Global Forecast Of Enzyme Inhibitor Class Revenues, Through 2011 ($ Millions)
    • Summary Figure: Percentage Of Revenues By Enzyme Inhibitor Class, In 2005 And 2011 (%)
  • Overview
    • Background
    • Enzymes
      • The Function Of Enzyme Inhibitors
      • Types Of Inhibitors
        • Competitive, Noncompetitive, And Uncompetitive
        • Reversible And Irreversible
        • Selective And Nonselective
      • Classes Of Enzyme Inhibitors
    • Cyclooxygenase Inhibitors
    • Dna Polymerase Inhibitors
    • Integrase Inhibitors
      • Hiv Integrase
    • Phosphodiesterase Inhibitors
    • Protease Inhibitors
      • Hiv Protease
    • Proton Pump Inhibitors (Atpase Inhibitors)
    • Transcriptase Inhibitors
      • Hiv Reverse Transcriptase
  • Products
    • Cox-2 Inhibitors
      • Cox-2 Products On The Market
        • Celebrex
        • Mobic
        • The Market For Cox-2 Inhibitors
      • Products Awaiting Fda Approval
      • Next-Generation Cox-2 Inhibitors
      • After-Effects Of The Withdrawal Of Vioxx And Bextra
        • Creating An Unwarranted Market?
        • The Fda Takes A Hard Look At Direct-To-Consumer Advertising
        • The Future Of Cox-2 Inhibitors
        • The Effect Of Insurance Company Reimbursement
    • Phosphodiesterase Inhibitors
      • Pde1 Inhibitors
      • Pde3 Inhibitors
        • Pde3 Inhibitors In Phase Ii Or Later Development
      • Pde4 Inhibitors
        • The Market For Pde4 Inhibitors
      • Product
        • Pde4 Inhibitors In Phase Ii Or Later Development
        • Ariflo
        • Awd12-281
        • Daxas
        • Ic485
        • Ono-6126
        • Drawbacks Of Pde4 Inhibitors Currently In Development
      • Pde5 Inhibitors
        • Marketed Products
        • Cialis
        • Levitra
        • Revatio
        • Viagra
        • Zydena
        • The Market For Pde5 Inhibitors
        • Pde5 Inhibitors In Phase Ii Or Later Development
        • Nm 702
        • Ta-1790
        • Tadalafil
      • Pde7 Inhibitors
      • Pde10 Inhibitors
    • Proton Pump Inhibitors
      • Aciphex/Pariet
      • Nexium
      • Prevacid
      • Prilosec/Losec
      • Pantozol
      • Protonix/ Protium
      • Takepron
      • Zegerid
      • Generic Proton Pump Inhibitors
      • Comparison Of Proton Pump Inhibitors
      • Cost Of Proton Pump Inhibitors
      • The Market For Proton Pump Inhibitors
    • Product
    • Transcriptase Inhibitors
      • Lack Of Incentive To Develop Drugs To Treat Hiv And Aids
      • The Impact Of The Availability Of Antiretroviral Therapy
      • The Introduction Of Haart
      • The First Generic Hiv/Aids Drug Enters The U.S. Market
      • Efforts To Reduce The Cost Of Hiv Drugs In The Developing World
        • Boehringer Ingelheim And Glaxosmithkline Sign Agreements
        • Aids Healthcare Foundation Lawsuit
        • Sub-Saharan Africa Generic Production Agreement
        • Merck Reduces The Cost Of Stocrin
      • Efforts To Make Generic Hiv Drugs Available In Developing Countries
        • The World Trade Organization Steps In
        • Generic Aids Drug Combinations Approved By The Fda For Emergency Aids Relief Plan
        • A Strategy To Gain A Foothold In The World Market
        • Clinton Foundation Negotiates Lower Drug Prices For Poor Countries
        • Other Struggles To Gain Access To Generic Hiv Drugs
      • "the 3 By 5 Initiative"
        • Main Plan Objectives
        • Status At The End Of 2005
      • Drug Resistance In Hiv/Aids
        • Definition Of Antiviral Drug Resistance
        • How Resistance Develops
        • Locations Of Mutations
        • Types Of Resistance
        • Current Status Of Resistance
        • 2003 Catch Study
        • Resistance Among Hiv Cases In Europe
        • Conclusions
        • Novel Drug Resistance Treatment Strategies
        • Acute Infection And Early Disease Research Program
        • Types Of Drug Resistance Testing
        • Genotypic And Phenotypic Testing
        • Genotypic Testing
        • Phenotypic Testing
        • Comparison Of Genotypic Versus Phenotypic Testing
        • Reimbursement For Hiv Drug Resistance Testing
        • Guidelines For Hiv Drug Resistance Testing
        • The Special Case Of Protease Inhibitors
        • The Rationale For Genotypic Testing For Hiv-I Drug Resistance
        • Available Hiv Drug Resistance Tests
      • Saliva Tests Approved To Detect Hiv
      • Cost Of Hiv/Aids Treatment
      • Abbott Increases The Cost Of Norvir Five-Fold
    • Available Products For The Treatment Of Hiv Infection And Aids
      • The Market For Enzyme-Inhibiting Products To Treat Hiv Infection And Aids
      • The U.S. Market For Enzyme-Inhibiting Hiv/Aids Drugs
      • Combination Products Emerge As Preferred Treatment
      • Leading Marketers Of Hiv/Aids Drugs
        • Leaders In The Nucleoside Reverse Transcriptase Inhibitor Class
      • Categories Of Enzyme-Inhibiting Drugs Available For The Treatment Of Hiv/Aids
        • Nonnucleoside Reverse Transcriptase Inhibitors
        • Nucleoside Reverse Transcriptase Inhibitors
        • Nucleotide Reverse Transcriptase Inhibitors
        • Protease Inhibitors
        • Side Effects Of Marketed Hiv Drugs
        • Adverse Cardiovascular Events
      • Selected Transcriptase-Inhibiting Drugs Introduced To The U.S. Market In 2003, 2004 And 2005
        • Nonnucleoside Reverse Transcriptase Inhibitors
        • Nucleoside Reverse Transcriptase Inhibitors
        • Emtriva
        • Epizicom
        • Truvada
        • Nucleotide Reverse Transcriptase Inhibitors
        • Protease Inhibitors
        • Aptivus
        • Lexiva/Telzir
        • Reyataz
      • Dosing And Compliance Challenges
      • The Ideal Treatment Regimen
      • The Number Of Salvage Patients Continues To Increase
      • Enzyme-Inhibiting Drugs In Development For The Treatment And/Or Prevention Of Hiv Infection And Aids
      • The Three Main Enzyme Targets For Antiretroviral Drugs
        • Integrase
        • Jtk-303
        • Mk-0518
        • Protease
        • Protease Inhibitors In Phase Ii Or Later Development
        • Brecanavir
        • Darunavir
        • Reverse Transcriptase
        • Nonnucleoside Reverse Transcriptase Inhibitors In Phase Ii Or Later Development
        • Calanolide A
        • Capravirine
        • Etravirine
        • Miv-150
        • Miv-210
        • Tmc-278
        • Nucleoside Reverse Transcriptase Inhibitors In Phase Ii Or Later Development
        • Alovudine
        • Amdoxovir
        • Dexelvucitabine
        • Elvucitabine
        • Racivir
        • Spd754
      • Transcriptase Inhibitors For The Treatment Of Other Viral Diseases
        • Marketed Transcriptase Inhibitors For The Treatment Of Other Viral Diseases
        • Nucleoside Analogs Introduced Between 2003 And 2005 For The Treatment Of Other Viral Diseases
        • Baraclude
        • The Market For Nucleoside Analogs To Treat Other Viral Diseases
        • Nucleoside Analogs In Phase Ii Or Later Development For Other Viral Diseases
        • Hepatitis B Virus Infection
        • Clevudine
        • Elvucitabine
        • Miv-210
        • Pradefovir Mesylate
        • Telbivudine
        • Tenofovir Disoproxil Fumarate
        • Valtorcitabine
        • Hepatitis C Virus Infection
        • Gs1392
        • Jtk-003
        • Valopicitabine
        • Viramidine
        • Vx-950
        • Herpesvirus Infections
        • Valomaciclovir
  • Applications
    • Asthma And Chronic Obstructive Pulmonary Disease
      • Asthma
      • Chronic Obstructive Pulmonary Disease
      • The Role Of Cytokines In Asthma And Copd
      • The Market For Enzyme Inhibiting Drugs To Treat Asthma And Copd
    • Benign Prostatic Hyperplasia
    • Cardiovascular Diseases
      • Congestive Heart Failure
      • Hypertension
      • Intermittent Claudication
      • Pulmonary Arterial Hypertension
      • The Market For Enzyme Inhibiting Drugs To Treat Cardiovascular Diseases
    • Erectile Dysfunction
      • The Market For Enzyme Inhibiting Drugs To Treat Erectile Dysfunction
    • Gastrointestinal Diseases
      • The Market For Enzyme Inhibiting Drugs To Treat Gastrointestinal Disorders
    • Hepatitis B Virus Infection
      • The Market For Enzyme Inhibiting Drugs To Treat Hepatitis B Infection
    • Hepatitis C Virus Infection
      • The Market For Enzyme Inhibiting Drugs To Treat Hepatitis C Infection
    • Herpesvirus Infections
      • Cytomegalovirus
      • Herpes Simplex Virus
      • Herpes Zoster Virus
      • The Market For Enzyme Inhibiting Drugs To Treat Herpesvirus Infections
    • Human Immunodeficiency Virus Infection And Acquired Immune Deficiency Syndrome
      • Hiv And Aids Statistics
        • Number Of Hiv/Living With Aids Cases In 2005 By Geographic Region
        • Geographic Region 2005 Percentage Of Global Hiv Cases By Geographic Region
        • New Hiv Cases In 2005 By Region
        • 2005 Aids Deaths By Region
        • Estimated Number Of Hiv Cases By Country In 2002 And 2010
      • Hiv Infection And Aids Cases In The U.S.
      • The Need For Better Access To Treatment
      • Enzyme Inhibitors To Treat Hiv/Aids
      • The Market For Enzyme Inhibiting Drugs To Treat Hiv Infection And Aids
    • Rheumatoid Arthritis And Related Inflammatory Diseases
      • The Market For Enzyme Inhibiting Drugs To Treat Rheumatoid Arthritis And Related
  • Company Profiles
    • Abbott Laboratories
      • Business Overview
      • Financial Information
      • Products
      • Corporate Strategy
    • Achillion Pharmaceuticals, Inc.
      • Business Overview
      • Products
      • Corporate Strategy
    • Altana Pharma
      • Business Overview
      • Financial Information
      • Products
      • Corporate Strategy
    • Bristol-Myers Squibb
      • Business Overview
      • Financial Information
      • Products
      • Corporate Strategy
    • Celgene Corporation
      • Business Overview
      • Financial Information
      • Products
      • Financial Information
      • Corporate Strategy
    • Gilead Sciences Inc.
      • Business Overview
      • Financial Information
      • Products
      • Corporate Strategy
    • Glaxosmithkline Plc
      • Business Overview
      • Financial Information
      • Products
      • Corporate Strategy
    • Icos Corporation
      • Business Overview
      • Financial Information
      • Products
      • Corporate Strategy
    • Idenix Pharmaceuticals, Inc.
      • Business Overview
      • Financial Information
      • Products
      • Corporate Strategy
    • Incyte Corporation
      • Business Overview
      • Financial Information
      • Products
      • Corporate Stragegy
    • Medivir Ab
      • Business Overview
      • Financial Information
      • Products
      • Corporate Strategy
    • Novartis Ag
      • Business Overview
      • Financial Information
      • Products
      • Corporate Strategy
    • Pfizer Corporation
      • Business Overview
      • Financial Information
      • Products
      • Corporate Strategy
    • Pharmasset, Inc.
      • Business Overview
      • Products
      • Corporate Strategy
    • Plexxikon, Inc.
      • Business Overview
      • Products
      • Corporate Strategy
    • Santarus, Inc.
      • Business Overview
      • Products
      • Corporate Strategy
    • Tibotec Pharmaceuticals Ltd.
      • Business Overview
      • Products
      • Corporate Strategy
    • Valeant Pharmaceuticals International
      • Business Overview
      • Financial Information
      • Products
      • Corporate Strategy
  • List Of Figures
    • Summary Table: Global Forecast Of Enzyme Inhibitor Class Revenues, Through 2011 ($ Millions)
    • Table 1 Enzyme Inhibitors By Class: Definition And Examples
    • Table 2 Global Market Forecast For Cox-2 Inhibitors By Product Through 2011 ($ Millions)
    • Table 3 U.S. Market Forecast For Cox-2 Inhibitors By Product Through 2011 ($ Millions)
    • Table 4 Global Market Forecast For Pde4 Inhibitors By Product, Through 2011 ($ Millions)
    • Table 5 U.S. Market Forecast For Pde4 Inhibitors By Product, Through 2011 ($ Millions)
    • Table 6 Pde4 Inhibitors In Phase Ii Or Later Development
    • Table 7 Global Market Forecast For Pde5 Inhibitors By Product, Through 2011 ($ Millions)
    • Table 8 U.S. Market Forecast For Pde5 Inhibitors By Product, Through 2011 ($ Millions)
    • Table 9 Pde5 Inhibitors In Phase Ii Or Later Development
    • Table 10 Branded Prescription Proton Pump Inhibitors And Suppliers
    • Table 11 Global Market Forecast For Prescription, Branded Proton Pump Inhibitors By Product, Through 2011 ($ Millions)
    • Table 12 U.S. Market For Prescription, Branded Proton Pump Inhibitors By Product, Through 2011 ($ Millions)
    • Table 13 Number Of Deaths From Aids In The U.S., 1988-2005
    • Table 14 Resistance Among Hiv-Positive Patients In Europe As Determined By The Catch Study
    • Table 15 Protease Mutations
    • Table 16 Reverse Transcriptase Mutations
    • Table 17 Advantages And Disadvantages Of Genotypic Versus Phenotypic Testing
    • Table 18 Estimated Annual Costs For Haart In U.S. And Sub-Saharan Africa
    • Table 19 Comparison Of Average Annual Cost Of Boosted* Protease Inhibitor-Based Hiv Treatment Regimens Before And After Norvir Price Increase
    • Table 20 Fda-Approved Drugs For The Treatment Of Hiv Infection/Aids
    • Table 21 Global Market Forecast For Enzyme-Inhibiting Hiv/Aids Therapeutics, Through 2011 ($ Millions)
    • Table 22 Global Market Forecast For Enzyme-Inhibiting Hiv/Aids Therapeutics By Product, Through 2011 ($ Millions)
    • Table 23 U.S. Market Forecast For Enzyme-Inhibiting Hiv/Aids Therapeutics, Through 2011 ($ Millions)
    • Table 24 Enzyme Inhibiting Product Introductions For The Treatment Of Hiv Infection, U.S.: 2002-2005
    • Table 25 Daily Dosage Requirements For Selected Hiv/Aids Therapies
    • Table 26 Relationship Between Compliance And Dosing Frequency
    • Table 27 Enzyme-Inhibiting Products In Phase Ii Or Later Development For The Treatment And/Or Prevention Of Hiv Infection/Aids
    • Table 28 Marketed Nucleoside Analog Inhibitors For The Treatment Of Other Viral Diseases
    • Table 29 Global Market Forecast For Nucleoside Analog-Based Drugs To Treat Other Viral Diseases, Through 2011 ($ Millions)
    • Table 30 Global Market Forecast For Enzyme Inhibiting Drugs To Treat Asthma And Copd, Through 2011 ($ Millions)
    • Table 31 Global Market Forecast For Enzyme Inhibiting Drugs To Treat Cardiovascular Diseases, Through 2011 ($ Millions)
    • Table 32 Global Market Forecast For Enzyme Inhibiting Drugs To Treat Erectile Dysfunction, Through 2011 ($ Millions)
    • Table 33 Global Market Forecast For Enzyme Inhibiting Drugs To Treat Gastrointestinal Disorders, Through 2011 ($ Millions)
    • Table 34 Global Market Forecast For Enzyme Inhibiting Drugs To Treat Hepatitis B Infection, Through 2011 ($ Millions)
    • Table 35 Global Market Forecast For Enzyme Inhibiting Drugs To Treat Hepatitis C Infection, Through 2011
    • Table 36 Global Market Forecast For Enzyme Inhibiting Drugs To Treat Herpesvirus Infections, Through 2011 ($ Millions)
    • Table 37 Estimated Number Of Persons Infected With Hiv/Living With Aids, Adults And Children, By Geographic Region, 2005
    • Table 38 Percentage Of Global Hiv Cases By Geographic Region, 2005
    • Table 39 Estimated Number Of People Newly Infected With Hiv, Adults And Children, By Geographic Region, 2005
    • Table 40 Estimated Number Of Deaths From Aids, Adults And Children, By Geographic Region, 2005
    • Table 41 Estimated Number Of People Infected With Hiv In Selected Countries, 2002 And 2010 (MILLION)
    • Table 42 Percent Of Patients Receiving Antiretroviral Treatment For Hiv Infection By Geographic Region
    • Table 43 Global Market Forecast For Enzyme Inhibiting Drugs To Treat Hiv Infection And Aids, Through 2011 ($ Millions)
    • Table 44 Global Market Forecast For Enzyme-Inhibiting Drugs To Treat Rheumatoid Arthritis And Related Inflammatory Diseases, Through 2011 ($ Millions)
    • Table 45 Gilead's Product Pipeline
    • Table 46 Glaxosmithkline's Enzyme Inhibitor Product Pipeline
    • Table 47 Incyte's Product Pipeline
    • Table 48 Medivir's Product Pipeline
  • List Of Figures
    • Summary Figure: Percentage Of Revenues By Enzyme Inhibitor Class, In 2005 And 2011 (%)
    • Figure 1 How An Enzyme Combines Two Chemicals
    • Figure 2 Competitive Inhibition
    • Figure 3 Noncompetitive Inhibition
    • Figure 4 Market Share Of Enzyme-Inhibiting Hiv/Aids Drugs By Product Category, Worldwide Sales: 2006 And 2011 ($ Millions)
    • Figure 5 U.S. Market Forecast For Enzyme-Inhibiting Hiv/Aids Therapeutics, 2004-2011 ($ Millions)
    • Figure 6 Global Market Forecast For Nucleoside Analog-Based Drugs To Treat Other Viral Diseases, 2004-2011 ($ Millions)
    • Figure 7 Global Market Forecast For Enzyme Inhibiting Drugs To Treat Asthma And Copd, 2004-2011 ($ Millions)
    • Figure 8 Global Market Forecast For Enzyme Inhibiting Drugs To Treat Cardiovascular Diseases, 2004-2011 ($ Millions)
    • Figure 9 Global Market Forecast For Enzyme Inhibiting Drugs To Treat Erectile Dysfunction, 2004-2011 ($ Millions)
    • Figure 10 Global Market Forecast For Enzyme Inhibiting Drugs To Treat Gastrointestinal Disorders, 2004-2011 ($ Millions)
    • Figure 11 Global Market Forecast For Enzyme Inhibiting Drugs To Treat Hepatitis B Infection, 2004-2011 ($ Millions)
    • Figure 12 Global Market Forecast For Enzyme Inhibiting Drugs To Treat Hiv Infection And Aids, 2004-2011 ($ Millions)